CDC HAN Advisory: COVID-19 Rebound After Paxlovid Treatment
5/24/22 — The CDC issued a Health Alert Network (HAN) Health Advisory to update healthcare providers, public health departments, and the public on the potential for recurrence of COVID-19 or “COVID-19 rebound.” Paxlovid continues to be recommended for early-stage treatment of mild to moderate COVID-19 among persons at high risk for progression to severe disease. Paxlovid treatment … Continue reading “CDC HAN Advisory: COVID-19 Rebound After Paxlovid Treatment”
AHRQ Technical Brief: Emergency Medical Service/911 Workforce Infection Control and Prevention Issues
AHRQ Technical Brief APIC comments AHRQ Technical Brief, April 22, 2022
CDC/ASPR Listening Session on Proposed Update to CMS CoP on Pandemic Reporting
5/17/22 — The CDC and the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) are holding virtual listening sessions on the proposed revision to hospital and critical access hospital Conditions of Participation (CoP) on hospital data reporting provisions for COVID-19 after the conclusion of the current public health emergency (PHE), as well as … Continue reading “CDC/ASPR Listening Session on Proposed Update to CMS CoP on Pandemic Reporting”
CDC Updates COVID-19 Pediatric Operational Planning Guide
5/17/22 — In anticipation of a COVID-19 vaccine for the under-5 population, CDC has updated the Pediatric Operational Planning Guide. Read the updated COVID-19 Vaccination for Children page on the CDC website. Access a direct link to the PDF of the guide.
FDA Expands Eligibility for Pfizer COVID Vaccine Booster Dose for Children Ages 5-11
5/17/22 — The FDA amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine to authorize the use of a single booster dose for individuals 5 to 11 years of age at least 5 months after completion of a primary series with the Pfizer vaccine. Read the FDA announcement.
Fagron Recalls SyrSpend SF Cherry Due to Microbial Contamination
5/13/22 — Fagron, Inc. is voluntarily recalling two lots of SyrSpend SF Cherry to the hospital, pharmacy, and distributor level out of an abundance of caution. The affected lots are potentially contaminated with Burkholderia gladioli. Fagron sells this product for the extemporaneous compounding of prescriptions for oral dosing. Exposure to contaminated product could lead to adverse events, which … Continue reading “Fagron Recalls SyrSpend SF Cherry Due to Microbial Contamination”
Woodside Acquisitions Recalls COVID-19 Antigen Tests
5/16/22 — Woodside Acquisitions Inc. is recalling the Oral Rapid SARS-CoV-2 Antigen Rapid Test Kit and the Joysbio SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold) because they were distributed to U.S. customers without authorization, clearance, or approval from the FDA. Read the FDA recall notice.
FDA Authorizes OTC COVID-19/RSV/Flu Test
5/16/22 — The FDA authorized the Labcorp Seasonal Respiratory Virus RT-PCR DTC Test for use without a prescription by individuals with symptoms of respiratory viral infection consistent with COVID-19. This is the first non-prescription test authorized to identify respiratory syncytial virus (RSV) and influenza A and B, as well as COVID-19, that allows an individual to … Continue reading “FDA Authorizes OTC COVID-19/RSV/Flu Test”
CDC HAN Alert: Updated Recommendations for Adenovirus Testing in Children with Hepatitis
5/11/22 — The CDC is issuing a Health Alert Network (HAN) Health Update to provide updated information and recommendations about an epidemiologic investigation of pediatric cases of hepatitis of unknown etiology in the United States. As of May 5, 2022, CDC and state partners are investigating 109 children with hepatitis of unknown origin across 25 states … Continue reading “CDC HAN Alert: Updated Recommendations for Adenovirus Testing in Children with Hepatitis”
Skippack SARS-CoV-2 Antigen Rapid Test Recalled
5/10/22 — SML Distribution LLC is recalling the Skippack Medical Lab SARS-CoV-2 Antigen Rapid Tests (Colloidal Gold). The FDA has identified this issue as a Class I recall, the most serious type of recall, because this test is not authorized, cleared, or approved by the FDA for distribution or use in the United States. The FDA … Continue reading “Skippack SARS-CoV-2 Antigen Rapid Test Recalled”